Pakistan Pharmaceutical: Listed Pharma Sector Analysis 3QFY25; Deregulation improved sales and margins - By Topline Research
09 May 2025
Pakistan listed pharmaceuticals sector’s earnings were up by 83% YoY to Rs8.0bn in 3QFY25. This jump in profitability is primarily attributed to higher net sales, improved gross margins, and a decline in finance cost. ......
Pakistan Pharma: CY24: Improving profitability prospects - By JS Research
27 Mar 2025
We analyse CY24 performance of the listed pharmaceutical sector, using a sample size of nine companies. The year remained positive for the sector, mainly due to stable currency and raw material prices, coupled with the deregulation of non-essential d...
Pharmaceuticals: Pakistan Listed Pharma Sector Analysis 2024 Deregulation improved sales and margins - By Topline Research
27 Mar 2025
Pakistan listed pharmaceuticals sector’s earnings were up 3.1x to Rs24.8bn in calendar year 2024. This jump in profitability is primarily attributed to higher net sales and improved gross margins. ......
Pakistan Pharmaceutical: Shines with outperformance; triggers ahead – By JS Research
23 Dec 2024
Pharma sector has outperformed the KSE-100 by 118% CYTD, after underperforming the market for 3-consecutive years Despite the rally, the sector remains attractive due to growing profitability driven by higher margins from deregulated nonessential dru...
Abbott Laboratories (Pakistan) Limited (ABOT): 9MCY24 Corporate Briefing Takeaways – By Taurus Research
17 Dec 2024
ABOT is a prominent pharmaceutical company in Pakistan, renowned for its expertise in the manufacturing and marketing of a wide range of pharmaceutical products. With two state-of-the-art manufacturing facilities located in Karachi, ABBOT operates ac...
Abbott Laboratories (Pakistan) Limited (ABOT): Corporate analyst briefing takeaways – By JS Research
17 Dec 2024
Abbott Laboratories (ABOT) conducted its corporate briefing today to discuss CY23 & 9MCY24 results and outlook. To recall, the company reported earnings of Rs3.9bn (EPS: Rs40.34) during 9MCY24. We present key highlights from the session. ......
Abbott Laboratories (Pakistan) Limited (ABOT): Corporate Briefing Notes – By Chase Research
17 Dec 2024
Abbott Pakistan's net sales increased by 13% YoY in CY23 to PKR 55.5 billion compared to PKR 49.3 billion in CY22. The growth was more pronounced in the 9MCY24 period, where net sales rose by 20% YoY, reaching PKR 49.6 billion against PKR 41.2 bi...
Pakistan Strategy: Strategy 2025 - Choosing the Right Direction Towards Stability – By IIS Research
12 Dec 2024
“The haystack is golden, but it’s the needle that will shine.” This sentiment captures the current state of Pakistan’s equity market. After a remarkable 70% CY24TD run-up in the KSE-100 Index, Pakistan’s equity market has undoubtedly rewarded investo...
Pharmaceuticals: 1QFY25 sector earnings up 4x – By Sherman Research
31 Oct 2024
Despite the fact that sector’s production remained flat during 2MFY25 versus last year (as reported in LSM figures by PBS), pharmaceutical sector emerged as a unicorn in these testing times, thanks to sharp recovery in gross margin. The industry post...
Pharmaceutical: Stay order set aside against deregulation of nonessential drugs – By Taurus Research
04 Apr 2024
On February 6th, 2024, the Interim Government granted approval for the deregulation of non-essential drugs, thereby exempting them from the Drug Act of 1976 and calling for amendments to the Drug Act Policy of 2018. Nonetheless, a petition filed in t...
Latest Research Reports
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025
13 Aug 2025